Glenmark Pharmaceuticals Europe Ltd Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Glenmark Pharmaceuticals Europe Ltd Pharmaceutical Import Records from India — 3 Products, $1.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Glenmark Pharmaceuticals Europe Ltd — Pharmaceutical Importer Profile (2026) | 3 Products, $1.6M Trade | TransData Nexus

Glenmark Pharmaceuticals Europe Ltd

Pharmaceutical Importer · United Kingdom · Respiratory Focus · $1.6M Total Trade · DGFT Verified

Glenmark Pharmaceuticals Europe Ltd is a pharmaceutical importer based in United Kingdom with a total trade value of $1.6M across 3 products in 3 therapeutic categories. Based on 78 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Glenmark Pharmaceuticals Europe Ltd sources from 3 verified Indian suppliers, with Glenmark Pharmaceuticals Limited accounting for 94.8% of imports.

Glenmark Pharmaceuticals Europe Ltd — Import Portfolio & Supplier Network

Glenmark Pharmaceuticals Europe Ltd import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Glenmark Pharmaceuticals Europe Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Glenmark Pharmaceuticals Limited	$13.0M	612	94.8%
Usv Private Limited	$498.7K	26	3.6%
Macleods Pharmaceuticals Limited

What Formulations Does Glenmark Pharmaceuticals Europe Ltd Import?

Formulation	Value	Ships
Ursodeoxycholic acid TAB 150MG 60s	$429.4K	9
Gabapentin glenmark 600 MG 100s	$362.6K	10
Montelukast 10MG filmcoated TAB 28s	$359.6K	28
Montelukast 10MG filmcoated TAB 28s	$355.8K	15
Tranylcypromine 10MG fc tabs 28s	$216.1K	5
Lercanidipine hcl 20MG tabs 28s	$201.0K	9
Gabapentin glenmark 600 MG 100s	$179.1K	4
Soprobec 50mcg/act pres inh SOL beclo,b.	$176.4K	6
Pharmaceuticals : lercanidipine hcl 20MG tabs 28s	$174.4K	4
Pharmaceuticals : lercanidipine hcl 20mgtabs 28s	$172.1K	4
Lercanidipine hcl 10MG tabs 28s	$152.9K	18
Soprobec 250mcg/act pres inh SOL beclo	$150.0K	3
Atovaquon glenmark 750MG/5ML os 250ML	$150.0K	3
Lercanidipine hcl 20MG tabs 28s	$140.5K	6
Soprobec 100mcg/act pres inh SOL	$136.3K	3

Glenmark Pharmaceuticals Europe Ltd imports 390 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Montelukast	Respiratory	$1.2M	70	0.7%	15
2	Efavirenz	Antivirals	$200.0K	4	0.3%	4
3	Emtricitabine	Antiviral & HIV Medications	$200.0K	4	0.2%	6

Glenmark Pharmaceuticals Europe Ltd imports 3 pharmaceutical products across 3 categories into United Kingdom totaling $1.6M.

Glenmark Pharmaceuticals Europe Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Glenmark Pharmaceuticals Europe Ltd is a private limited company incorporated on 10 February 2004, headquartered at 2-B Laxmi House, Draycott Avenue, Kenton, Harrow, Middlesex, HA3 0BU, United Kingdom. (find-and-update.company-information.service.gov.uk) As a subsidiary of Glenmark Pharmaceuticals Limited, an Indian multinational pharmaceutical company founded in 1977, Glenmark Pharmaceuticals Europe Ltd plays a pivotal role in the distribution and marketing of pharmaceutical products across Europe. The company focuses on providing high-quality, affordable medications, particularly in therapeutic areas such as respiratory, dermatology, and oncology.

2Distribution Network

Glenmark Pharmaceuticals Europe Ltd operates a robust distribution network across the United Kingdom and other European markets. While specific warehouse locations are not publicly disclosed, the company's strategic presence in key European countries, including the UK, Germany, the Netherlands, Spain, Denmark, Sweden, and Ireland, indicates a well-established logistics infrastructure. This extensive network enables efficient distribution and supply chain management, ensuring timely delivery of pharmaceutical products to meet market demands.

3Industry Role

In the United Kingdom's pharmaceutical supply chain, Glenmark Pharmaceuticals Europe Ltd functions primarily as a wholesaler and distributor. The company imports finished pharmaceutical formulations from India, focusing on therapeutic areas such as respiratory, dermatology, and oncology. By leveraging its parent company's manufacturing capabilities and its own distribution network, Glenmark Pharmaceuticals Europe Ltd effectively bridges the gap between Indian pharmaceutical manufacturers and the UK market, ensuring the availability of essential medications to healthcare providers and patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Glenmark Pharmaceuticals Europe Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Glenmark Pharmaceuticals Europe Ltd's sourcing strategy exhibits a high degree of concentration, with 94.8% of its imports from India supplied by Glenmark Pharmaceuticals Limited. This single-source dependency may present risks, such as supply chain disruptions or pricing fluctuations. However, the substantial volume of shipments (612) and the long-standing relationship between the companies suggest a stable and reliable partnership. The remaining imports are sourced from USV Private Limited (3.6%) and Macleods Pharmaceuticals Limited (1.6%), indicating a diversified yet still concentrated supplier base.

2Supply Chain Resilience

The resilience of Glenmark Pharmaceuticals Europe Ltd's Indian supply chain is bolstered by its reliance on a limited number of suppliers. While this concentration can lead to vulnerabilities, the company's extensive portfolio of 390 unique formulations imported from India provides a level of diversification. Additionally, the established relationships with suppliers like Glenmark Pharmaceuticals Limited, USV Private Limited, and Macleods Pharmaceuticals Limited, all of which are reputable manufacturers, contribute to the overall stability and reliability of the supply chain.

3Strategic Implications

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing pharma imports includes the Human Medicines Regulations 2012, which transposes EU directives into UK law, and the Medicines Act 1968. The marketing authorization pathway for Indian generics involves obtaining a Marketing Authorization (MA) from the MHRA, which can be achieved through the Centralized Procedure for new active substances or the National Procedure for generics and biosimilars.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the UK mandate that all medicines, including generics, must have a valid Marketing Authorization (MA) issued by the MHRA. Manufacturers and importers must comply with Good Manufacturing Practice (GMP) standards, with recognition of EU GMP, WHO GMP, and PIC/S certifications. Wholesale distribution authorization is also required, ensuring that entities involved in the distribution chain meet the necessary regulatory standards to maintain product quality and safety.

3Quality & Labeling

Glenmark Pharmaceuticals Europe Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Glenmark Pharmaceuticals Europe Ltd's focus on importing products in the respiratory, dermatology, and oncology therapeutic areas aligns with market demand for treatments in these segments. The company's portfolio includes 390 unique formulations, indicating a diverse range of products within these categories. This strategic focus allows Glenmark to address critical healthcare needs and leverage its parent company's expertise in these therapeutic areas.

2Sourcing Profile

Glenmark Pharmaceuticals Europe Ltd's sourcing strategy emphasizes generic drug procurement, particularly in the respiratory, dermatology, and oncology segments. The company's reliance on Indian manufacturers, especially Glenmark Pharmaceuticals Limited, reflects a strategic choice to leverage cost efficiencies and established supplier relationships. This approach enables Glenmark to offer a diverse range of high-quality, affordable medications to the UK market.

3Market Positioning

Based on its product mix, Glenmark Pharmaceuticals Europe Ltd serves multiple segments of the UK pharmaceutical market, including retail pharmacies, hospitals, and wholesale distribution. The company's focus on essential therapeutic areas positions it to meet the needs of various healthcare providers and patients, ensuring broad access to critical medications.

Seller's Guide — How to Become a Supplier to Glenmark Pharmaceuticals Europe Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the UK market by aligning their product offerings with Glenmark Pharmaceuticals Europe Ltd's therapeutic focus areas. Gaps in Glenmark's current sourcing, such as specific formulations or dosage forms, present potential entry points for new suppliers. Establishing relationships with Glenmark could facilitate market entry and distribution within the UK.

2Requirements & Qualifications

Indian exporters seeking to supply Glenmark Pharmaceuticals Europe Ltd and the UK market must obtain a valid Marketing Authorization from the MHRA. Compliance with EU GMP, WHO GMP, or PIC/S certifications is essential to meet quality standards. Additionally, adherence to UK labeling requirements, including English language labeling and serialization mandates, is necessary to ensure regulatory compliance.

3How to Approach

Indian exporters should initiate contact with Glenmark Pharmaceuticals Europe Ltd by presenting their product portfolios and demonstrating compliance with UK regulatory standards. Participating in relevant tenders and industry conferences can enhance visibility and facilitate networking opportunities. Developing a comprehensive regulatory filing strategy, including obtaining necessary certifications and approvals, is crucial. Timelines for regulatory approvals can vary; therefore, proactive engagement and thorough preparation are essential for successful market entry.

Frequently Asked Questions — Glenmark Pharmaceuticals Europe Ltd

What products does Glenmark Pharmaceuticals Europe Ltd import from India?

Glenmark Pharmaceuticals Europe Ltd imports 3 pharmaceutical products across 3 categories. Top imports: Montelukast ($1.2M), Efavirenz ($200.0K), Emtricitabine ($200.0K).

Who supplies pharmaceuticals to Glenmark Pharmaceuticals Europe Ltd from India?

Glenmark Pharmaceuticals Europe Ltd sources from 3 verified Indian suppliers. The primary supplier is Glenmark Pharmaceuticals Limited (94.8% of imports, $13.0M).

What is Glenmark Pharmaceuticals Europe Ltd's total pharmaceutical import value?

Glenmark Pharmaceuticals Europe Ltd's total pharmaceutical import value from India is $1.6M, based on 78 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Glenmark Pharmaceuticals Europe Ltd focus on?

Glenmark Pharmaceuticals Europe Ltd imports across 3 categories. The largest: Respiratory (75.6%), Antivirals (12.2%), Antiviral & HIV Medications (12.2%).

Get Full Glenmark Pharmaceuticals Europe Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.